138 related articles for article (PubMed ID: 31515627)
21. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
22. K27M midline gliomas display malignant progression by imaging and histology.
Vettermann FJ; Neumann JE; Suchorska B; Bartenstein P; Giese A; Dorostkar MM; Albert NL; Schüller U
Neuropathol Appl Neurobiol; 2017 Aug; 43(5):458-462. PubMed ID: 27997032
[No Abstract] [Full Text] [Related]
23. Identification of differentially expressed genes and fusion genes associated with malignant progression of spinal cord gliomas by transcriptome analysis.
Liu DK; Wang J; Guo Y; Sun ZX; Wang GH
Sci Rep; 2019 Sep; 9(1):13583. PubMed ID: 31537867
[TBL] [Abstract][Full Text] [Related]
24. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
Kleinschmidt-DeMasters BK; Mulcahy Levy JM
Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
[TBL] [Abstract][Full Text] [Related]
25. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Lee J; Solomon DA; Tihan T
J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387
[TBL] [Abstract][Full Text] [Related]
26. Cervical cord tumor in two haemophilic brothers.
Blaauw G; Schenk VW
J Neurol Sci; 1971 Dec; 14(4):409-16. PubMed ID: 5125755
[No Abstract] [Full Text] [Related]
27. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.
Castel D; Kergrohen T; Tauziède-Espariat A; Mackay A; Ghermaoui S; Lechapt E; Pfister SM; Kramm CM; Boddaert N; Blauwblomme T; Puget S; Beccaria K; Jones C; Jones DTW; Varlet P; Grill J; Debily MA
Acta Neuropathol; 2020 Jun; 139(6):1109-1113. PubMed ID: 32193787
[No Abstract] [Full Text] [Related]
28. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
[TBL] [Abstract][Full Text] [Related]
29. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
[TBL] [Abstract][Full Text] [Related]
30. Invited Review: Emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas.
Kasper LH; Baker SJ
Neuropathol Appl Neurobiol; 2020 Feb; 46(1):73-85. PubMed ID: 31859390
[TBL] [Abstract][Full Text] [Related]
31. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
32. [Gliomas and BRCA genes mutations: fortuitous association or imputability?].
Girardstein-Boccara L; Mari V; Met-Domestici M; Burel-Vandenbos F; Berthet P; Paquis P; Frenay MP; Lebrun-Frenay C
Bull Cancer; 2014 Sep; 101(9):795-802. PubMed ID: 25295380
[TBL] [Abstract][Full Text] [Related]
33. Genomic Landscape of Intramedullary Spinal Cord Gliomas.
Zhang M; Iyer RR; Azad TD; Wang Q; Garzon-Muvdi T; Wang J; Liu A; Burger P; Eberhart C; Rodriguez FJ; Sciubba DM; Wolinsky JP; Gokaslan Z; Groves ML; Jallo GI; Bettegowda C
Sci Rep; 2019 Dec; 9(1):18722. PubMed ID: 31822682
[TBL] [Abstract][Full Text] [Related]
34. Diffuse Midline Gliomas without the H3 K27M Mutation: Surgical Biopsy is Needed to Better our Diagnostic Understanding.
Lu VM; Raghunathan A; Schwartz JD; Daniels DJ
World Neurosurg; 2020 May; 137():472-473. PubMed ID: 32365434
[No Abstract] [Full Text] [Related]
35. Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.
Taylor AJ; Frobisher C; Ellison DW; Reulen RC; Winter DL; Taylor RE; Stiller CA; Lancashire ER; Tudor EC; Baggott C; May S; Hawkins MM
J Clin Oncol; 2009 Dec; 27(34):5781-7. PubMed ID: 19786666
[TBL] [Abstract][Full Text] [Related]
36. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
Feng J; Hao S; Pan C; Wang Y; Wu Z; Zhang J; Yan H; Zhang L; Wan H
Hum Pathol; 2015 Nov; 46(11):1626-32. PubMed ID: 26297251
[TBL] [Abstract][Full Text] [Related]
37. K27/G34 versus K28/G35 in histone H3-mutant gliomas: A note of caution.
Leske H; Rushing E; Budka H; Niehusmann P; Pahnke J; Panagopoulos I
Acta Neuropathol; 2018 Jul; 136(1):175-176. PubMed ID: 29766298
[No Abstract] [Full Text] [Related]
38. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
39. Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations.
Schüller U; Iglauer P; Dorostkar MM; Mawrin C; Herms J; Giese A; Glatzel M; Neumann JE
Acta Neuropathol; 2021 Feb; 141(2):323-325. PubMed ID: 33433639
[No Abstract] [Full Text] [Related]
40. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
